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A fatal case of a pulmonary infection caused by Hormographiella aspergillata, the anainorph of the mushroom 
Coprinus cinereus, is reported for a patient receiving treatment for a second relapse of acute lymphoblastic 
leukemia. The filamentous basidiomycete was identified with restriction fragment length polymorphism pat­
terns of PCR-amplified internally transcribed spacers and small subunit ribosomal DNA with four restriction 
enzymes. The patient failed to respond to treatment with amphotericin B and itraconazole. The fungus was 
cultured from the lungs at autopsy: the MIC of amphotericin B for the fungus was low (0.5 mg/liter), and that 
of itraconazole was high (8 mg/liter).
Aspergillus fumiga tits is the most common cause of fungal 
pneumonia in immunocompromised patients (2), although 
other filamentous fungi such as ncm-fumigatus Aspergillus spe­
cies, Fusarium species, zygomycetes, and Scedosporium apio- 
spermum are noted (2, 8). Until now, filamentous basidiomy- 
cetes are rarely reported  as a cause of invasive infections (10, 
1 1 ), despite the fact that airborne spores are abundantly 
present in the environm ent and that several species grow well 
at 37°C. Hormographiella is a new hyphomycete genus, de­
scribed by G uarro  et ah (9) in 1992, which has three species: H. 
aspergillata, H. verticillata, and / / .  candelabrata. IL aspergillata 
was found to be the anam orph  of the mushroom Coprinus 
cinereus (7). H ere , we report a case of fatal pneumonia due to 
H. aspergillata in a patient receiving intensive cytotoxic trea t­
ment.
A 24-year-old man was diagnosed with acute lymphoblastic 
leukemia in 1988. l i e  responded to intensive induction, con­
solidation, and m aintenance therapy. A first relapse was diag­
nosed in 1993, and treatm ent with peripheral stem-cell trans­
plantation resulted in complete remission. However, a relapse 
was diagnosed for the second time in September 1995. Cyto­
toxic therapy was initiated, and after 13 days while he was still 
granulocytopenic, he developed fever again despite empiric 
ceftazidime therapy. Cultures of blood and oral lesions re­
mained sterile, and radiographs of the chest were unrevealing. 
On day 18, he complained of right-sided pleuritic chest pain, 
and a new chest radiograph showed focal pulmonary infiltrates 
in the right lower lobe. Because of severe respiratory insuffi­
ciency, a diagnostic intervention (biopsy or lung lavage) was 
not possible. T rea tm en t with amphotericin B desoxycholate (1 
mg/kg/of body weight per day) was started on suspicion of 
invasive aspergillosis. A  chest radiograph made on day 23 
showed progression of the right-sided infiltrate, and new infil­
trates in the left upper and lower lobes of the lung. The patient 
remained profoundly neutropenic  with fever and headache. A  
right-sided hemiparesis developed, but a computed tomogra­
phy scan of the brain was normal. Therapy with amphotericin 
B was changed to itraconazole (400 mg/day) on day 26 because
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of amphotericin B-associated nephrotoxicity. By then the pa­
tient had received a cumulative dose of 310 mg of am photer­
icin B. The clinical condition deteriorated rapidly, and the 
patient died from respiratory failure on day 35,
An autopsy was performed 20 h after death. Tissue samples 
were obtained from all major organs and from any macro­
scopic abnormalities, fixed in 10% formalin, embedded in par­
affin, sectioned at 5 |ini, and stained with periodic acid-Schiff, 
Gomori methenamine silver with eosin counterstain, or hema­
toxylin and eosin. Tissue samples were obtained aseptically for 
microbiological cultures from the lungs, liver, spleen, and kid­
neys; homogenized (Stomacher 80 Lab-Blcnder; Seward M ed­
ical, London, United Kingdom); and streaked onto sheep 
blood agar plates and Levine medium and then were incubated 
at 37°C for 48 h. Homogenized tissue samples were also 
streaked onto Sabouraud glucose (2%) agar containing chlor­
amphenicol and incubated at 28 and 42°C for 4 days. Identifi­
cation of the cultured fungus was performed by PCR amplifi­
cation of DNA with primers NS1 and NS24 (amplicon small 
subunit [SSU]) and internally transcribed spacers (ITS) 1 and
4 primers (amplicon ITS1 and 2, including 5.8S ribosomal 
D N A  [rDNA]) (17), Amplicons were digested with the restric­
tion enzymes Hinfi, Haelll, Rsal, and Ddel and clectropho- 
resed on 1.4% agarose gels (Fig. 1). Representative strains of 
Schizophyllum commune, Coprinus cinereus, Phanerochaete 
chrysosporium, Sporotrichum dimorphosum, and Bjerkandera 
adusta and type strains of H. aspergillata, &  candelabrata, and 
H. verticillata were run on the same gels. Patterns were com­
pared by using the Image M aster (Pharmacia, Roosendaal, 
The Netherlands) software package for evaluation of molecu­
lar weights. Antifungal susceptibility testing was performed by 
the agar incorporation m ethod with R P M I-1640 agar buffered 
with 0.165 M  morpholinepropanesulfonic acid (MOPS) with 
0.03% (wt/vol) L-glutamine added (5). Doubling dilutions of 
amphotericin B (Bristol-Myers Squibb, W oerden, The N eth­
erlands), fluconazole (Pfizer, Capeile a/d Ussel, The N ether­
lands), itraconazole (Janssen-Cilag Biotech, Tilburg, The 
Netherlands), and voriconazole (Pfizer, Sandwich, United 
Kingdom) from 64 to 0.03 mg/liter were prepared in 2~ml 
volumes of sterile water. Volumes (18 ml) of molten agar were 
added, and the components were mixed, poured into petri 
dishes, and allowed to set. Spore suspensions were adjusted to 
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help to recognize basidiomycetes when cultured from clinical 
specimens (15).
Overall, the incidence of opportunistic fungal infections is 
increasing, and the epidemiology is changing. Until 10 years 
ago, Candida species were found to be the most frequent cause 
of fungal infection in hematologic patients at autopsy, followed 
by Aspergillus species (2). Now A . famigatus has become the 
most important pathogen, and the number of unidentified or 
novel fungal pathogens is increasing (8). Although the number 
of emerging fungal pathogens causing infection in hematologic 
patients at present is low, the rising incidence may call for a 
more profound diagnostic approach. For each granulocytope­
nic patient who is suspected of a fungal infection, the risk of 
obtaining a specimen by bronchoscopy or by an invasive pro­
cedure for histology and culture is weighed against the risk of 
treating the patient empirically without a correct diagnosis. 
The latter approach was frequently followed because the phy­
sician relied on the expectation that the number of possible 
fungal pathogens was limited and that all would be susceptible 
to first-line antifungal agents such as amphotericin B or itra­
conazole. The present case illustrates that this approach may 
fail, because clinical signs and symptoms produced by emerg­
ing fungi and the radiological presentation are indistinguish­
able from invasive aspergillosis, but the susceptibility to first- 
line or, in our case, second-line antifungal agents may vary.
At present, limited data about the susceptibility of Homo- 
graphiella species to antifungal agents are available. C. cinereus 
and H. verticillata were previously found to be susceptible to 
antifungal azoles (with the exception of fluconazole), variably 
susceptible to amphotericin B, and resistant to flucytosine by 
use of a broth microdilution method (7). However, in the 
present study, two different susceptibility tests suggested that 
H. aspergillata may be resistant to itraconazole. Since the num­
ber of infections by unusual fungi is increasing, reproducible 
and meaningful in vitro tests need to be developed for suscep­
tibility testing of these fungi, and the correlation of the MICs 
with clinical outcome needs to be ascertained. Clearly, this 
field of research will need to be addressed in the near future.
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